Proglumide has access to brain and antagonizes the central satiety effect of cholecystokinin octapeptide in the dog.
Intra-third cerebroventricularly administered cholecystokinin octapeptide (CCK-8) decreased food intake through central mechanisms in the dog. Proglumide, administered intravenously, did enter into cerebrospinal (ventricular) fluid, and partially, but significantly, reversed this effect. CR1409, one of the newly synthesized glutaramic derivatives, blocked CCK-8-induced satiety more strongly than proglumide. These results indicate that systemic proglumide and CR1409 result in antagonism of the central CCK receptor for satiety in the dog.
D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004327:Drinking Behavior / Q000187:drug effects; D005247:Feeding Behavior / Q000187:drug effects; D005973:Glutamine / Q000031:analogs & derivatives*; D007262:Infusions, Intravenous; D007276:Injections, Intraventricular; D011377:Proglumide / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D012527:Satiation / Q000187:drug effects*; D012528:Satiety Response / Q000187:drug effects*; D012844:Sincalide / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
D005973:Glutamine; D011377:Proglumide; C048181:lorglumide; D012844:Sincalide